2 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.
April 2019 in “Journal of Investigative Dermatology” Lichen planopilaris involves disrupted fat metabolism, increased scarring, and mast cell activity.
Not having the gene PLAAT3 leads to fat loss, high insulin resistance, and abnormal fat levels in the blood due to a disruption in fat cell development and function.
2 citations
,
September 2024 in “PLoS ONE” Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
2 citations
,
January 2025 in “Journal of Nanobiotechnology” A new engineered treatment shows promise in curing heart fibrosis.
23 citations
,
August 1983 in “PubMed” Clq deficiency is linked to systemic lupus erythematosus symptoms.
19 citations
,
January 2001 in “Internal Medicine” Protein-losing enteropathy worsened with lupus symptoms but improved with prednisolone.
Ca²⁺-mediated protein citrullination controls cell growth in the CNS and may help treat brain tumors.
14 citations
,
October 2015 in “PLoS ONE” Keratin 14 is uniquely found in a specific group of placental cells.
17 citations
,
October 2021 in “Cellular & Molecular Biology Letters” New biomarkers and potential treatments for skin diseases were identified.
133 citations
,
May 2016 in “Cell Host & Microbe” Human dermal fibroblasts are the main cells targeted by a virus that can cause a deadly skin cancer, and a certain inhibitor can effectively block this infection.
April 2023 in “Journal of Investigative Dermatology” Being allergic to linalool, a common fragrance ingredient, might contribute to developing frontal fibrosing alopecia.
4 citations
,
April 2024 in “Cellular and Molecular Biology” Injectable platelet-rich fibrin is better than platelet-rich plasma for promoting hair growth.
2 citations
,
February 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” Impaired LEF1 activation speeds up skin cell development in Hutchinson-Gilford Progeria Syndrome.
April 2019 in “Journal of Investigative Dermatology” FGFR2 signaling controls Merkel cell formation in different skin regions.
March 2024 in “International Journal of Cosmetic Science” Dandruff is linked to increased T cells and weakened immune protection in hair follicles.
21 citations
,
September 1990 in “Journal of The American Academy of Dermatology” Taking L-tryptophan supplements might cause a condition similar to scleroderma in some people, which can get better after stopping the supplement and starting corticosteroid therapy.
4 citations
,
February 2023 in “Stem Cell Research & Therapy” Mouse skin cells can become sperm-like cells in the lab.
Newly designed proteins can effectively degrade specific proteins in cells, offering a potential new therapy method.
Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.
6 citations
,
January 2020 in “International journal of biological sciences” Removing the ROBO4 gene in mice reduces skin inflammation and hair loss by affecting certain inflammation pathways and gene expression.
107 citations
,
October 2022 in “Frontiers in Immunology” T cells and inflammation are crucial in atherosclerosis, with anti-inflammatory treatments showing promise.
January 2024 in “Inflammation and regeneration” Th22 cells are essential for Tβ15-induced hair growth in mice.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Too much IKZF1 and Ikaros protein may cause alopecia areata.
59 citations
,
November 2011 in “Development” Trps1 is essential for proper hair follicle development.
Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” The early genes of a specific virus can cause abnormal skin cell growth and hair follicle changes.
April 2011 in “The FASEB Journal” Profilin1 speeds up wound healing.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.